This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drugdevelopment has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drugdevelopment.
Navigating the complex landscape of drugdevelopment and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. This can offer advantages in terms of continuity and efficiency.
Drug repurposing’s potential to target undruggable molecules is showing huge promise for its ability to accelerate the development of new therapies and improve patient outcomes. They also provide a level playing field for academics, biotech companies, and pharma giants to compete on.
Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies. This is why not many Pharmacompanies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes.
Therapiesdeveloped in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.
Drug Policy There will be significant changes in clinical trials & drugdevelopment due to the Inflation Reduction Act. As pharmaceutical companies shift their focus toward fewer, high-value therapeutic areas in light of the IRAs drug price negotiations, the overall number of clinical trials will go down.
As pharmacompanies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces.
Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.
As pharmacompanies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients. Source link.
Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drugdevelopment, and medical education.
From co-founding Acerta Pharma to pioneering patient-centric innovations, Dr. Hamdy shares his impactful career. Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals.
With its technology, the company wants to change the way that biopharma companies plan clinical trials and develop oncology drugs. This is all about getting the right drugs to the right patients at the right time as soon as possible to personalize the treatment of their therapies, primarily in oncology,” said Vennare.
Yohan Tessier, Vice President of Commercial Operations & Strategic Development at Mispro, explained that this is critical in expediting their clients’ time to market. We’re seeing a trend in drugdevelopment towards super complex and highly-targeted compounds, which requires researchers to conduct a number of preclinical studies.
With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drugdevelopers with the tools, insights, and support needed to advance their therapies from concept to clinic. We are driving rapid analytics to support the release of cell and gene therapies and other biologics.
Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Always free.
In hopes to advance the best and brightest, MD Anderson, in partnership with The Focus Fund GP, has launched the Cancer Focus Fund to propel compelling investigational cancer therapies from preclinical development through Phase II clinical trials. But now they’ll be choosing the therapies themselves. .
Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drugdevelopment and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards.
The examples : 1) a health care provider posting on the internet about unsubstantiated claims that a class of cholesterol drugs causes Alzheimer’s; 2) a celebrity influencer recommending off-label use (i.e., In fact, a “big pharma” company denying the accuracy of a claim may even serve to legitimize that claim in the eyes of some people.
Planning the journey from data to deliverables The future of AI-enabled drugdevelopment benefits from the continued advancement of multimodality and clinical genomics, with a focus on integration, efficiency and personalisation to transform both care and R&D. Techbio companies have initiated this approach.
It is a strong potential player in the gene therapy space. Its lead candidate is AMT-061, an AAV5-based gene therapy being evaluated for severe and moderately severe hemophilia B in the Phase III HOPE-B study. billion, Regenxbio is also a gene therapycompany. UniQure has a market cap of $2.1 With a market cap of $1.6
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content